中等强度胰岛素治疗与危重糖尿病酮症酸中毒和高渗高血糖状态患者住院时间缩短相关
该预-后研究在美国一家大型学术医疗中心纳入2010年10月至2014年12月连续201例因糖尿病酮症酸中毒和高渗高血糖状态入院的非妊娠成人患者,比较高强度胰岛素治疗与中等强度胰岛素治疗。中等强度策略避免弹丸式给药、放宽血糖目标并缓慢滴定胰岛素。结果显示住院和ICU时间分别缩短23.6%和38%,第7天和第14天仍住院的相对风险及48小时仍住ICU的相对风险均显著降低,低血糖患病率(35% vs 1%)和相对风险显著降低,血糖变异性降低28.6%,阴离子间隙闭合时间无差异。
要点
- 中等强度胰岛素治疗使住院时间缩短23.6%、ICU时间缩短38%,并降低第7天(RR 0.51)和第14天(RR 0.28)仍住院的相对风险。
- 中等强度组48小时仍住ICU的相对风险为0.34(p=0.0048),显著低于高强度组。
- 低血糖患病率中等强度组1% vs 高强度组35%(p=0.0003),相对风险0.028(p=0.0004)。
- 血糖变异性降低28.6%(p<0.0001),阴离子间隙闭合时间两组无差异(p=0.123)。
- 中等强度策略包括避免弹丸式胰岛素、放宽血糖目标并缓慢滴定,适用于因糖尿病酮症酸中毒和高渗高血糖状态入院的非妊娠成人。
适用人群与场景
- 2010年10月至2014年12月在美国一家大型学术医疗中心连续入院的非妊娠成人糖尿病酮症酸中毒和高渗高血糖状态患者,共201例。
处置流程与药物剂量
- 中等强度胰岛素治疗:避免弹丸式胰岛素给药、放宽血糖目标、缓慢滴定胰岛素。
- 高强度胰岛素治疗:采用弹丸式胰岛素和快速滴定以快速使血糖正常化。
研究设计与关键结果
- 预-后研究,纳入201例连续非妊娠成人糖尿病酮症酸中毒和高渗高血糖状态患者,比较中等强度与高强度胰岛素治疗。
- 住院时间缩短23.6%,ICU时间缩短38%。
- 第7天仍住院的相对风险0.51(p=0.022),第14天仍住院的相对风险0.28(p=0.044),中等强度组显著降低。
- 48小时仍住ICU的相对风险0.34(p=0.0048),中等强度组显著低于高强度组。
- 低血糖患病率中等强度组1% vs 高强度组35%(p=0.0003),相对风险0.028(p=0.0004)。
- 血糖变异性降低28.6%(p<0.0001)。
- 阴离子间隙闭合时间两组无差异(p=0.123)。
证据类型、等级与局限
- 证据类型:预-后研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于因糖尿病酮症酸中毒和高渗高血糖状态入院的非妊娠成人,中等强度胰岛素治疗(避免弹丸式给药、放宽血糖目标、缓慢滴定)与住院和ICU时间缩短及低血糖减少相关。
- 中等强度策略未延长阴离子间隙闭合时间,提示其可能在不延误酸中毒纠正的情况下减少低血糖和血糖变异性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Insulin infusion therapy is commonly used in the hospital setting to manage diabetic ketoacidosis and hyperosmolar hyperglycemic state. Clinical evidence suggests both hypoglycemia and glycemic variability negatively impact patient outcomes. The hypothesis of this study was that moderate-intensity insulin therapy decreases hospital length of stay and prevalence of hypoglycemia in patients with diabetic ketoacidosis and hyperosmolar hyperglycemic state.
DESIGN: Pre-post study.
SETTING: Large academic medical center in the United States.
PATIENTS: Two-hundred one consecutive, nonpregnant, adult patients admitted for diabetic ketoacidosis and hyperosmolar hyperglycemic state between October 2010 and December 2014.
INTERVENTIONS: High-intensity insulin therapy versus moderate-intensity insulin therapy. High-intensity insulin therapy was designed to rapidly normalize blood glucose levels with bolus doses of insulin and rapid insulin titration. Moderate-intensity insulin therapy was designed to mitigate glycemic variability and hypoglycemia through avoidance of bolus dosing, a liberalized blood glucose target, and gradual insulin titration.
MEASUREMENTS AND MAIN RESULTS: Hospital and ICU length of stay were reduced by 23.6% and 38%, respectively. The relative risk of remaining in the hospital at day 7 (0.51; p = 0.022) and day 14 (0.28; p = 0.044) were significantly reduced by the moderate-intensity insulin therapy strategy. The relative risk of remaining in the ICU at 48 hours was significantly lower in the moderate-intensity insulin therapy cohort (0.34; p = 0.0048). The prevalence (35% vs 1%; p = 0.0003) and relative risk (0.028; p = 0.0004) of hypoglycemia were significantly lower in the moderate-intensity insulin therapy cohort. Glycemic variability decreased by 28.6% (p < 0.0001). There was no difference in the time to anion gap closure (p = 0.123).
CONCLUSIONS: Moderate-intensity insulin therapy for diabetic ketoacidosis and hyperosmolar hyperglycemic state resulted in improvements in hospital and ICU length of stay, which appeared to be associated with decreased glycemic variability.
参考来源
- Firestone RL, Parker PL, Pandya KA, et al. Moderate-Intensity Insulin Therapy Is Associated With Reduced Length of Stay in Critically Ill Patients With Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State. Crit Care Med. 2019. PMID: 30855284. doi:10.1097/CCM.0000000000003709
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。